883 - Stool Toxin Concentrations Are Higher in Children with Baseline Severe Disease, Severe Outcomes, and Recurrence

Presenting Author(s)

• 

  Thomas J. Sandora, MD, MPH

  Hospital Epidemiologist
  Boston Children's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose

  Slides

Co-Author(s)

• 

  Larry K. Kociolek, MD, MSCI

  Attending Physician
  Ann & Robert H. Lurie Children’s Hospital of Chicago
  Chicago, Illinois, United States

  Disclosure: Disclosure(s): Merck: Grant/Research Support ()
• DW

  David N. Williams, PhD

  Boston Children's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• KD

  Kaitlyn Daugherty, n/a

  Clinical Research Assistant II
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• CG

  Christine Geer, MPH

  Boston Children's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• CC

  Christine Cuddemi, n/a

  Clinical Research Coordinator
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• XC

  Xinhua Chen, PhD

  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• HX

  Hua Xu, n/a

  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• 

  Timothy J. Savage, MD, MPH, MSc

  Attending Physician / Instructor in Medicine
  Boston Children's Hospital / Brigham and Women's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): UCB: Contract to Brigham and Women's Hospital ()
• AB

  Alice Banz, PhD

  Staff scientist
  biomerieux
  Marcy L’Etoile, Auvergne, France

  Disclosure: Disclosure(s): biomerieux: Simoa assays were performed by bioMerieux, and A.B. is an employee of bioMerieux ()
• 

  Kevin W. Garey, PharmD, MS (he/him/his)

  Professor and Chair
  University of Houston
  Houston, TX, United States

  Disclosure: Disclosure(s): Acurx: Grant/Research Support (); cidara: Advisor/Consultant (), Grant/Research Support (); Paratek: Grant/Research Support (); Seres Health: Grant/Research Support (); Summit: Grant/Research Support ()
• 

  Anne J. Gonzales-Luna, PharmD, BCIDP (she/her/hers)

  Assistant Professor
  University of Houston
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• CK

  Ciaran P. Kelly, n/a

  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): Artugen: Advisor/Consultant (); Facile Therapeutics: Advisor/Consultant (); Ferring Pharma: Advisor/Consultant (); Finch: Advisor/Consultant (), Advisor/Consultant (); First Light Biosciences: Advisor/Consultant (), Ownership Interest (); Milky Way Biosciences: Advisor/Consultant (), Grant/Research Support (); Pfizer: Advisor/Consultant (); Seres Therapeutics: Advisor/Consultant (); Summit Therapeutics: Advisor/Consultant ()
• 

  Nira R. Pollock, MD, PhD

  Associate Medical Director, Infectious Diseases Diagnostic Lab/Associate Professor of Pathology and Medicine
  Boston Children's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose